Business Context and Reporting Period
This Form 8-K Current Report was filed by Calidi Biotherapeutics, Inc. (CLDI) on December 12, 2023, covering events occurring on November 8, 2023, and December 10, 2023. The filing primarily addresses the entry into a Standby Equity Purchase Agreement (SEPA) and changes to the Board of Directors.
Key Financial Metrics and Agreements
The filing details a liquidity facility rather than historical financial performance metrics such as revenue or profit.
- SEPA Commitment: The Company entered into an agreement with YA II PN, Ltd. ("Yorkville") to sell up to $25,000,000 of Common Stock over 36 months.
- Potential Expansion: Subject to conditions and an additional fee, the commitment amount may be increased by an additional $25,000,000.
- Pricing: Shares are purchased at 97.0% of the Market Price.
- Ownership Limits: Yorkville's beneficial ownership is capped at 4.99% of outstanding shares. Total issuance under the SEPA is capped at 19.9% of outstanding shares as of December 10, 2023 (Exchange Cap).
- Upfront Costs: The Company paid a $25,000 structuring fee and issued $250,000 worth of Commitment Fee Shares to Yorkville.
The filing text does not provide clear values for revenue, net income, operating cash flow, gross margins, total debt, or current liquidity positions.
Material Changes
The primary material change is the establishment of the SEPA, providing the Company with a mechanism to raise capital on demand. Additionally, the Board composition changed with the resignation of Thomas Vecchiolla and the appointment of David LaPre, effective January 1, 2024.
Outlook, Risks, and Contingencies
- Conditions Precedent: Yorkville's obligation to purchase shares is contingent upon the filing and effectiveness of a registration statement with the SEC.
- Regulatory Compliance: Issuances exceeding the 19.9% Exchange Cap require compliance with NYSE American rules.
- Management Commentary: The resignation of Mr. Vecchiolla is attributed to personal reasons and explicitly stated as not being due to any disagreement regarding operations, policies, or accounting practices.
- Unusual Items: The issuance of Commitment Fee Shares represents an immediate dilution event tied to the agreement execution.
Investor Verification Checklist
- Verify the effectiveness of the SEPA Registration Statement required for the agreement to be fully operational.
- Confirm the exact number of Commitment Fee Shares issued based on the 10-day VWAP calculation.
- Monitor the Company's cash burn rate to assess the necessity of utilizing the SEPA facility.
- Review the full text of the SEPA (Exhibit 10.1) for specific termination rights and additional fees beyond the initial commitment.
- Assess the impact of the 4.99% beneficial ownership limitation on the speed of capital raises.